{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.53","upperLimit":"14.55","value":"11.79"},{"groupId":"OG001","lowerLimit":"5.06","upperLimit":"9.66","value":"6.44"},{"groupId":"OG002","lowerLimit":"7.20","upperLimit":"12.29","value":"10.12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"119"}],"units":"Participants"}],"description":"Time from start of treatment to death","dispersionType":"95% Confidence Interval","groups":[{"description":"Melphalan flufenamide (melflufen) 40 mg Day 1 and dexamethasone 40 mg (reduced dose for patients 75 years or older) on Days 1, 8, 15 and 22 of each 28-day cycle.\n\nMelphalan flufenamide (Melflufen)\n\nDexamethasone: IV dexamethasone may be substituted for oral dexamethasone in the US. Oral only in Europe.","id":"OG000","title":"Melphalan Flufenamide (Melflufen) + Dexamethasone: Full Analysis Set"},{"description":"Patients with extramedullary disease at baseline defined as myeloma disease either originating in, but extending beyond, the cortical bone or as a separate soft tissue mass","id":"OG001","title":"Melphalan Flufenamide (Melflufen) + Dexamethasone: Patients With Extramedullary Disease"},{"description":"Triple class refractory population defined as refractory to or intolerant of at least one immunomodulatory drug, at least one proteasome inhibitor, and at least one anti-CD38 monoclonal antibody","id":"OG002","title":"Melphalan Flufenamide (Melflufen) + Dexamethasone: Patients With Triple Class Refractory Disease"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set.","reportingStatus":"POSTED","timeFrame":"From date of first dose of study medication until the date of death from any cause, assessed up to 24 months after study drug discontinuation.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}